A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Фаза 3
Завершено
NCT06238817
| Заболевание | Atopic Dermatitis |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Incyte Corporation |
|---|
| Статус | Завершено |
|---|
| Участники | 241 участн. |
|---|
| Вмешательство | Ruxolitinib Cream, Vehicle Cream |
|---|
| Дата начала | 26.04.2024 |
|---|
| Дата завершения | 21.05.2025 |
|---|
| Публикация результатов | 22.05.2026 |
|---|
Кратко
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 18.5 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 70.0 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 11.26 (95% CI 5.692–22.260) |
|---|
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 13.6 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 61.3 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 10.14 (95% CI 4.904–20.975) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.